Tesla shuts down Shanghai plant over supply issues: Report

Tesla shuts down Shanghai plant over supply issues: Report

Tesla had planned as late as last week to increase output to pre-lockdown levels by next week

AgenciesUpdated: Tuesday, May 10, 2022, 01:22 PM IST
article-image
The US automaker has halted most of its production at the plant due to problems securing parts. / Representative image | File Photo

Tesla has decided to shut down its Shanghai plant on Tuesday amid tightening COVID lockdown. The factory was functioning well below capacity on Tuesday, according to Reuters.

The US automaker has halted most of its production at the plant due to problems securing parts, according to an internal memo seen by Reuters.

Tesla had planned as late as last week to increase output to pre-lockdown levels by next week. Among Tesla suppliers facing difficulties is wire harness maker Aptiv after infections were found among its employees, sources said on Monday, Reuters said.

Many of the hundreds of companies reopening factories in Shanghai in recent weeks have faced challenges getting production lines back up to speed while keeping workers on-site in a "closed loop" system, the report said.

(With inputs from Reuters)

RECENT STORIES

FPIs Pull Out ₹11,820 Crore In Early December, Rupee Slide & Global Uncertainty Shake Indian...

FPIs Pull Out ₹11,820 Crore In Early December, Rupee Slide & Global Uncertainty Shake Indian...

Wakefit Raises ₹186 Crore Ahead Of ₹1,289-Crore IPO As Steadview, WhiteOak And Capital 2B Buy...

Wakefit Raises ₹186 Crore Ahead Of ₹1,289-Crore IPO As Steadview, WhiteOak And Capital 2B Buy...

Top Companies Add Massive Value In A Weak Market, TCS & Infosys Lead The Weekly Surge

Top Companies Add Massive Value In A Weak Market, TCS & Infosys Lead The Weekly Surge

SoftBank-Backed AceVector Files Updated IPO Papers With Sebi; Plans ₹300-Crore Fresh Issue And...

SoftBank-Backed AceVector Files Updated IPO Papers With Sebi; Plans ₹300-Crore Fresh Issue And...

Biocon’s Bold Bet On Biologics, A Restructuring Move That Could Redefine Its Future & Move The...

Biocon’s Bold Bet On Biologics, A Restructuring Move That Could Redefine Its Future & Move The...